Xiaojun Huang

Title: Xiaojun Huang - Innovator in Medical Research

Introduction

Xiaojun Huang is a notable inventor based in Beijing, China. He has made significant contributions to the field of medical research, particularly in the areas of cancer therapy and immunoregulation. Although he currently holds no granted patents, his work is focused on innovative methods that could potentially transform treatment approaches.

Latest Patent Applications

Xiaojun Huang's latest patent applications include:

1. **Use of CD90+ Human Amniotic Epithelial Cells in Treatment of Graft Versus Host Disease** - This application describes a method for treating subjects suffering from graft versus host disease (GvHD) or those at risk of developing it. The method involves selecting a CD90hAEC cell population with enhanced immunoregulation capabilities as a primary therapeutic cell. Research indicates that the stem cell pluripotent markers SSEA4, OCT4, and NANOG in CD90hAECs are significantly higher than in general hAECs, leading to improved immunomodulatory functions and better clinical outcomes.

2. **Methods for Cancer Therapy** - This application relates to methods for treating patients with cancer, including those with hematological malignancies. The method comprises administering a therapeutically effective amount of a specific compound, or a pharmaceutically acceptable salt thereof, to the patient.

Conclusion

Xiaojun Huang is an innovative inventor whose research has the potential to impact medical treatments significantly. His focus on advanced therapeutic methods showcases his commitment to improving patient outcomes in challenging medical conditions.